💰 Financial Record

This document is page 42 of a confidential investment strategy memorandum for NLV-III (New Leaf Ventures III). It details the strategy for investing in 'Biological Research Tools & Infrastructure,' highlighting the benefits of lower regulatory risks compared to biopharma and aiming for companies near the commercial stage. The document notes that up to 15% of the fund will be allocated to this sector and medical devices, citing 'Advanced Cellular Diagnostics' from the previous NLV-II fund as a successful example.